TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06366932

Intervention type: DRUG
Group type: OTHER
Intervention: Second-line systemic treatment
Description: Patients with moderate to severe atopic dermatitis refractory to topical medication, who also have previous experience with cyclosporine and an unsatisfactory response, or in whom the use of cyclosporine is considered inappropriate due to contraindication or intolerance, are candidates for treatment with other alternatives (Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib).

Intervention type: OTHER
Group type: OTHER
Intervention: Folllow-up of second-line systemic treatment already started
Description: If the patient is receiving second-line therapy at the moment of the inclusion, data will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.
Study: NCT05141591

Intervention type: OTHER
Intervention: Anxiety level assessment
Description: To investigate the impact of psychological variables e.g. pre-surgical anxiety on postoperative opioid consumption and pain level, the investigators will perform the STOA, APAIS, PCS and the VAS-A anxiety questionnaires before surgery.
Study: NCT05477693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental 23-valent PPV
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
Study: NCT05913960

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
Study: NCT05477693

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control 23-valent PPV
Description: The control vaccine was manufactured by Merck Sharp \& Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
Study: NCT04877483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
Study: NCT05913960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: accelerated intermittent theta burst stimulation
Description: Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high frequency stimulation
Description: Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
Study: NCT04421196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusion of opioid analgesics
Description: The intervention involves removing the option of patients having an opioid analgesic at any time point during the perioperative period.
Study: NCT04877483

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral microbiota
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral microbiota
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral microbiota
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral microbiota
Description: Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Schirmer's test
Description: Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Schirmer's test
Description: Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Schirmer's test
Description: Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tear breakup time
Description: Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
Study: NCT04738500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block combinated with PCA
Description: After spinal anesthesia PENG block will be performed

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PCA
Description: PCA will be applied after surgery
Study: NCT05577156

Intervention type: BEHAVIORAL
Intervention: Self-questionnaires and semi-structured interview
Description: Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions
Study: NCT06446388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2, intravenous infusion, D1, up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2, intravenous infusion, D1, up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, oral, bid, D1-D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, oral, bid, D1-D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, oral, bid, D1-D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
Study: NCT04877483

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tear breakup time
Description: Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tear breakup time
Description: Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
Study: NCT06446388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg, intravenous infusion,D1
Study: NCT06261450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral Solution (eCBD system Target)
Description: Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral Solution (eCBD system Target)
Description: Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)
Study: NCT04460573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boot
Description: Smart boot in one of three configurations provided to participants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boot
Description: Smart boot in one of three configurations provided to participants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boot
Description: Smart boot in one of three configurations provided to participants
Study: NCT05451199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-488
Description: ICP-488 will be administered as tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablet
Study: NCT06489860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIV
Description: Directions: For adults and for Children 1-12 years old. Indication: Anti-AIDS Drug. Ingredient: Organic Rice 91% and Honey 9% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoplasms
Description: Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Rice 90% and Honey 10% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date.
Study: NCT05662891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.
Study: NCT06501079

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Erector Spinae Plane Block using 27ml bupivacaine 0.25%
Description: ESP block will be performed U/S at the level of T 10 paraspinal level. The ultrasound transducer should be placed in the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level.~Erector spinae muscle should be identified superficial to the transverse process. The needle inserted superior to the ultrasound probe in the cephalad to caudal direction. Once the needle tip is below the erector spinae muscle.~This separation from the transverse process confirms the proper needlemposition.~The local anesthetic should then be injected in 5 ml increments. The block will be performed preoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Erector Spinae Plane Block using 27ml bupivacaine 0.25%
Description: ESP block will be performed U/S at the level of T 10 paraspinal level. The ultrasound transducer should be placed in the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level.~Erector spinae muscle should be identified superficial to the transverse process. The needle inserted superior to the ultrasound probe in the cephalad to caudal direction. Once the needle tip is below the erector spinae muscle.~This separation from the transverse process confirms the proper needlemposition.~The local anesthetic should then be injected in 5 ml increments. The block will be performed preoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Erector Spinae Plane Block using 27ml bupivacaine 0.25%
Description: ESP block will be performed U/S at the level of T 10 paraspinal level. The ultrasound transducer should be placed in the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level.~Erector spinae muscle should be identified superficial to the transverse process. The needle inserted superior to the ultrasound probe in the cephalad to caudal direction. Once the needle tip is below the erector spinae muscle.~This separation from the transverse process confirms the proper needlemposition.~The local anesthetic should then be injected in 5 ml increments. The block will be performed preoperatively.
Study: NCT06074380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIST surfactant
Description: Surfactant will be given via MIST while neonate is on CPAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIST surfactant
Description: Surfactant will be given via MIST while neonate is on CPAP
Study: NCT06554132

Intervention type: OTHER
Intervention: Scleroderma Group
Description: Scleroderma patients will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.

Intervention type: OTHER
Intervention: Healthy group
Description: Healthy people will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
Study: NCT04893980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-2 (rhIL-2)
Description: During Day 0-14, patients in this group will receive treatment with antihistamines at the same dosage as pre-recruitment, together with a low-dose recombinant human Interleukin-2 (rhIL-2) at a dosage of 1 million international units every other day by intramuscular injection (rhIL-2, 1 MIU, im, Qod). During Day 15-28, the injections of rhIL-2 will be continued at the same dosage and the dose of antihistamines may be adjusted according to the control of symptoms.

Intervention type: DRUG
Group type: OTHER
Intervention: Control group
Description: During Day 0-14, patients in the control group receive treatment with only antihistamines at the same dosage as pre-recruitment, but no injection of rhIL-2. During Day 15-28, treatment with low dose recombinant human Interleukin-2 (rhIL-2), i.e., 1 million international units every other day by subcutaneous or intramuscular injection (rhIL-2, 1MIU, im, Qod), will be added.
Study: NCT04874571

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle Energy Technique group
Description: In addition to the home exercise program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the MET(Musculer Energy Technique) group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique group
Description: In addition to the home exercise program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the MET(Musculer Energy Technique) group.
Study: NCT05465811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program of physical exercises and health education by telerehabilitation
Description: To carry out the telerehabilitation program, the Google Meet platform will be used in order to provide the synchronous service model. This will occur for a period of 16 weeks, three weekly sessions lasting 50 minutes, (total of 48 sessions). The sessions will be given by physiotherapists and students in their final year of graduation in physiotherapy, which will consist of the following phases: initial rest, warm-up, resistance exercises, stretching exercises, relaxation and final rest.~In addition, in exchange for the warm-up phase, every 12 sessions, the telerehabilitation program also will have an approach through health education, using presentations, digital booklets and direct conversation between therapist and participants. The themes exhibited (importance of physical exercise in the pandemic context, reduction of the risk of falls through changes in the home environment and physiological changes resulting from aging) will intend to make them aware of better lifestyle habits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program of physical exercises and health education by telerehabilitation
Description: To carry out the telerehabilitation program, the Google Meet platform will be used in order to provide the synchronous service model. This will occur for a period of 16 weeks, three weekly sessions lasting 50 minutes, (total of 48 sessions). The sessions will be given by physiotherapists and students in their final year of graduation in physiotherapy, which will consist of the following phases: initial rest, warm-up, resistance exercises, stretching exercises, relaxation and final rest.~In addition, in exchange for the warm-up phase, every 12 sessions, the telerehabilitation program also will have an approach through health education, using presentations, digital booklets and direct conversation between therapist and participants. The themes exhibited (importance of physical exercise in the pandemic context, reduction of the risk of falls through changes in the home environment and physiological changes resulting from aging) will intend to make them aware of better lifestyle habits.
Study: NCT06175923

Intervention type: BIOLOGICAL
Intervention: Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care
Description: When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.

Intervention type: BIOLOGICAL
Intervention: Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care
Description: When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
Study: NCT06250270

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: protein or placebo
Description: casein protein (30g) or placebo (maltodextrin, 30g)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein or placebo
Description: casein protein (30g) or placebo (maltodextrin, 30g)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein or placebo
Description: casein protein (30g) or placebo (maltodextrin, 30g)
Study: NCT06495307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPRG4
Description: Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride \& 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated
Study: NCT05466383

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise rehabilitation with Schroth method

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise rehabilitation with Schroth method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brace
Description: Wear an orthopedic brace

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brace
Description: Wear an orthopedic brace
Study: NCT05580705

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: The Routine Physiotherapy treatment will include Transcutaneous Electrical Nerve Stimulation, Hot pack, Range of Motion (ROM) Exercises and Muscle Strengthening Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration Therapy
Description: Vibration Therapy will include a vibration device of brand Manipol, model number RK-001. It has 360 degree off-centered axis with a frequency of 2500 times per minute. It will be applied on sole of the foot for about 15 mins.
Study: NCT01280669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injection 440mcg
Description: Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of sirolimus 880mcg
Description: Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
Study: NCT05160389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200
Description: Single dose of PBI-200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200
Description: Single dose of PBI-200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200
Description: Single dose of PBI-200
Study: NCT04781179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM-II
Description: It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation
Study: NCT05433142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb819
Description: Monoclonal Bispecific Antibody
Study: NCT05120804

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard behavioral treatment
Description: Nutrition and physical activity education along with behavior modification techniques

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment plus relationship skills training
Description: Nutrition and physical activity education along with behavior modification techniques plus relationship skills training